Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sertraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 0.72 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.72 |
| ▸ | NPC1 | O15118 | 2/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.72 |
| ▸ | MTOR | P42345 | 2/20 | 0.72 |
| ▸ | RAB9A | P51151 | 2/20 | 0.72 |
| ▸ | MLNR | O43193 | 1/20 | 0.72 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | ESR1 | P03372 | 1/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.72 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.72 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sertraline SCHEMBL3786157 | 1.00 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL6700902 | 1.00 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL6442184 | 1.00 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL7933194 | 1.00 | SLC6A4 (0.72) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL5146578 | 0.90 | SLC6A4 (0.77) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL5146585 | 0.90 | SLC6A4 (0.77) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL1208326 | 0.90 | SLC6A4 (0.77) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL29248769 | 0.89 | SLC6A4 (0.87) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL6442186 | 0.89 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 | |
| Sertraline SCHEMBL1206649 | 0.88 | SLC6A4 (0.85) | SLC6A4SLC6A2SLC6A3CYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109627174-A | A kind of preparation method of chiral sertraline hydrochloride | 上虞京新药业有限公司 | 2019-04-16 | — | — | CN | claimed |
| US-20100204470-A1 | METHOD FOR SALT PREPARATION | SANDOZ AG | 2010-08-12 | — | — | US | claimed |
| US-7772438-B2 | Process of making sertraline form I | HETERO DRUGS LIMITED (IN) | 2010-08-10 | — | — | US | claimed |
| WO-2010076763-A2 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF SERTRALINE | PIRAMAL HEALTHCARE LIMITED (IN) | 2010-07-08 | — | — | WO | claimed |
| US-20090177010-A1 | PROCESS OF MAKING SERTRALINE FORM I | HETERO DRUGS LIMITED (IN) | 2009-07-09 | — | — | US | claimed |
| US-7518019-B2 | Processes for preparing sertraline hydrochloride crystalline forms | HETERO DRUGS LIMITED (IN) | 2009-04-14 | — | — | US | claimed |
| US-7518018-B2 | Processes for preparing sertraline | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-04-14 | — | — | US | claimed |
| EP-2032521-A2 | NEW METHOD FOR SALT PREPARATION | Sandoz AG (CH) | 2009-03-11 | — | — | EP | claimed |
| EP-2033947-A1 | Novel processes for preparing sertraline hydrochloride crystalline forms | Hetero Drugs Limited (IN) | 2009-03-11 | — | — | EP | claimed |
| US-20090023955-A1 | Novel process for the preparation of sertraline hydrochloride form II | APOTEX PHARMACHEM INC. | 2009-01-22 | — | — | US | claimed |
| WO-2003093217-A1 | PROCESS FOR PREPARATION OF POLYMORPHIC FORM II OF SERTRALINE HYDROCHLORIDE, PHARMACEUTICAL FORMULATIONS AND METHODS OF ADMINISTRATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-11-13 | — | — | WO | claimed |
| WO-2003051818-A1 | A NOVEL POLYMORPH OF SERTRALINE HYDROCHLORIDE AND COMPOSITION CONTAINING THEREOF, NOVEL METHODS FOR PREPARATION OF SERTRALINE HYDROCHLORIDE POLYMORPHS AND AMORPHOUS FORM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-06-26 | — | — | WO | claimed |
| US-6517866-B1 | Oral administration at controlled rate; side effect reduction | PFIZER INC. | 2003-02-11 | — | — | US | claimed |
| US-6495721-B1 | MAKING SERTRALINE HYDROCHLORIDE FORM II FROM SERTRALINE BASE OR SERTRALINE MANDELATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2002-12-17 | — | — | US | claimed |
| WO-2002096859-A1 | PROCESS FOR PREPARING SERTRALINE HYDROCHLORIDE POLYMORPHIC FORM II | ORION CORPORATION FERMION (FI) | 2002-12-05 | — | — | WO | claimed |
| US-20020183555-A1 | Sertraline hydrochloride form II and methods for the preparation thereof | SCHWARTZ EDUARD (IL) | 2002-12-05 | — | — | US | claimed |
| JP-2000514101-A | — | — | 2000-10-24 | — | — | JP | claimed |
| CN-1261793-A | Sertraline salts and sustained release dosage forms of sertraline | PFIZER (US) | 2000-08-02 | — | — | CN | claimed |
| EP-0999830-A1 | SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE | PFIZER INC. (US) | 2000-05-17 | — | — | EP | claimed |
| WO-1999001121-A1 | SERTRALINE SALTS AND SUSTAINED-RELEASE DOSAGE FORMS OF SERTRALINE | PFIZER INC. (US) | 1999-01-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090177010-A1 | PROCESS OF MAKING SERTRALINE FORM I | HTR5A, HTR2A, HTR2C | SLC6A4 6/4885SLC6A2 22/4885SLC6A3 104/4885 |
| US-20020183555-A1 | Sertraline hydrochloride form II and methods for the preparation thereof | HTR5A, SLC6A4, HTR2C | SLC6A4 2/4885SLC6A2 9/4885SLC6A3 25/4885 |
| US-20090023955-A1 | Novel process for the preparation of sertraline hydrochloride form II | TPH2, HTR5A, HTR2A | SLC6A4 5/4885SLC6A2 12/4885SLC6A3 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.